{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "PACB",
  "name": "Pacific Biosciences of California, Inc.",
  "url": "https://frontierpicks.com/dossiers/PACB/",
  "json_url": "https://frontierpicks.com/dossiers/PACB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Pacific Biosciences' shares have climbed back to about $2.60, up 80.9% in three months, on partner news and a Stephens target raise, while revenue is flat and gross margin is 32%. The 4 November 2026 Q3 report decides whether reported numbers catch up.",
  "invalidation_trigger": "A daily close below $2.10, which would erase the advance made since the 2026-10-23 close of $2.11; secondarily, a Q3 2026 report that cuts the $155–165M revenue guide or shows GAAP gross margin below Q2's 32%.",
  "catalyst_date": "2026-11-04",
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "$644.3M of convertible senior notes were outstanding against $236.9M of cash and investments as of the Q2 2026 report (2026-08-05).",
    "Mark Van Oene became President and CEO on 2026-08-05, succeeding Christian Henry.",
    "PacBio sold short-read sequencing intellectual property and related assets to Illumina in February 2026 for $48.1M in net cash proceeds.",
    "StockStory counted 87 single-session moves larger than 5% over the year to 2026-10-05; double-digit daily swings are within the stock's observed range.",
    "The Q3 2026 results are due after the market close on 2026-11-04; the call starts at 4:30 p.m. ET."
  ],
  "source_links": [],
  "body_markdown": "## Current Thesis\n\nPacific Biosciences (PacBio) shares have recovered to about $2.60, an 80.9% gain over three months, while the business reported in August is unchanged: flat revenue and a 32% gross margin. The Q3 2026 report on 2026-11-04 decides whether reported numbers catch up with the price.\n\nThe last adjusted daily close was about $2.60 on 2026-10-30, 10.2% below the 52-week high of about $2.90. The 14-day relative strength index (RSI), a 0–100 momentum gauge, reads 62.7. The shares closed at $1.73 on 2026-10-16 and $2.11 on 2026-10-23 (AAII), so the price has moved about 50% in two weeks. The $1.62 level in the previous note, the close before the first rally, was not breached.\n\nNew since 2026-10-20: a headline on 2026-10-24 that Stephens maintained a Buy rating and raised its target, a headline on 2026-10-31 that ARK Invest increased its holdings, and company notice on 2026-10-27 of November investor conference appearances. The narrative is still maturing: the Verily Health and TychoBio announcements are well known, and the new buying has come from analyst and fund-holding headlines, not from new company-reported results. Q2 2026 revenue was $39.0M against $39.8M a year earlier, and GAAP (generally accepted accounting principles) gross margin was 32% against 37% (8-K, 2026-08-05).\n\n## Bull Case\n\n- **Verily brings HiFi into biomedical AI.** PacBio and Verily Health announced a multi-year collaboration on 2026-10-19 to pair HiFi long-read genomes with clinical data on Verily's Pre platform for AI model training (BioSpace, StreetInsider).\n- **AI drug-discovery demand for RNA data.** TychoBio will sequence more than 10,000 samples with HiFi and Kinnex RNA kits to train rare-disease RNA therapy models (PacBio release, 2026-10-06).\n- **Sell-side sentiment is improving.** A headline on 2026-10-24 reports that Stephens maintained its Buy rating and raised its price target; the new figure was not available in the sources checked.\n- **Government-funded Revio volume.** Sampled won a five-year Department of Veterans Affairs contract worth up to $27.1M on 2026-09-28 for the Million Veteran Program on PacBio Revio systems (StockStory, 2026-09-28).\n- **Revio grew and costs are coming out.** Revio placements rose to 20 from 15 a year earlier (Q2 release, 2026-08-05). A restructuring approved on 2026-07-30 targets $30–40M of annualized operating-expense cuts by the end of 2027 (8-K, 2026-07-30).\n\n## Bear Case\n\n- **Revenue is flat and missed estimates.** Q2 2026 revenue of $39.0M trailed the prior year's $39.8M (8-K, 2026-08-05) and the $42.9M consensus estimate (MarketBeat). The $155–165M full-year guide needs a heavier second half.\n- **Gross margin is falling.** GAAP gross margin was 32% in Q2 2026 against 37% a year earlier (8-K, 2026-08-05).\n- **Debt dwarfs cash.** Convertible senior notes outstanding were $644.3M against $236.9M of cash and investments on 2026-08-05, which leaves open an equity raise or note exchange.\n- **An insider sold into the earlier spike.** James Gibson II sold 661,815 shares at an average of $3.11 on 2026-10-06 under a Rule 10b5-1 plan, according to MarketBeat's summary of the Form 4.\n- **The price sits above published targets.** MarketBeat's consensus target across six brokerages was $1.71 with a \"Reduce\" rating on 2026-10-16. UBS's target was $1.35 (2026-09-09) and Barclays' $1.25 (2026-08-05). Those figures predate the latest rise and the Stephens change.\n\n## Setup & Price Structure\n\nThe shares closed at about $2.60 on 2026-10-30, adjusted daily close. The 52-week high is about $2.90, set in the 2026-10-05 spike, and October's intraday high was $3.44 (AAII). The mid-August low was roughly $1.07–$1.11, so the shares have more than doubled from it.\n\nCrowding evidence is visible. The earnings report is two sessions away, the stock has 87 single-session moves above 5% over the year to 2026-10-05 (StockStory), an insider sold into the October spike, and fund-holding headlines coincide with the advance. The shares have not yet re-tested the $3.11 insider sale price or the $3.44 intraday high.\n\nThe level that matters on the downside is the $2.11 close of 2026-10-23, the last close before the latest advance. A daily close below $2.10 would erase it.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-11-09: UBS Global Healthcare Conference.** UBS is Neutral with a $1.35 target (2026-09-09).\n- **2026-11-16: Jefferies Global Healthcare Conference.**\n- **2026-11-18: Stephens NASH26 Conference.**\n\nConference dates come from PacBio's 2026-10-27 announcement as relayed by news aggregators.\n\n## Elapsed catalysts\n\n- **2026-11-04: Q3 2026 results**, 4:30 p.m. ET call. The test is revenue against Q3 2025's $38.4M and the $155–165M guide, Revio and Vega placements, and gross margin against 32%. *(passed 2d ago)*\n\n## What Would Change Our Mind\n\nThe case for a rating above coverage-only needs reported numbers to move. A Q3 report that cuts the $155–165M guide, shows revenue below $38.4M, or shows gross margin below 32% would show the partner announcements are not reaching the income statement. An equity offering or note exchange would add a second reason. A daily close below $2.10 would erase the latest advance.\n\nIn the other direction, Q3 revenue above the prior-year quarter, gross margin above 32% and a reaffirmed or raised guide would give the partner story company-reported support. One quarter would not settle the debt question, since $644.3M of convertible notes remains against $236.9M of cash.\n\n## Correlation Notes\n\nPacBio trades with small-cap life-science tools and genomics names, and its largest moves have come on company announcements and fund-flow headlines. Illumina and Oxford Nanopore are the direct competitors in long-read and methylation sequencing, and the February 2026 sale of PacBio's short-read assets to Illumina for $48.1M in net cash proceeds links the two. The shares carry a high-beta, sentiment-driven profile.",
  "first_seen": "2026-09-30",
  "last_analyzed": "2026-11-02T05:19:59+00:00",
  "last_synthesized": "2026-11-02",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}